Storia in 5 fonti

Twice-Rejected Melanoma Drug Gets Surprise Love From FDA Panel

Vote at odds with FDA reviewers

Raccontata da

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

medpagetoday.comStai leggendo3 g fa

Twice-Rejected Melanoma Drug Gets Surprise Love From FDA Panel

Vote at odds with FDA reviewers

originale

biopharmadive.com

Timeline cronologica

martedì 28 luglio 2026·medpagetoday.com
FDA Staff Unconvinced Drug for Melanoma Shows Benefit
Replimune's RP1 faces tough test at upcoming FDA advisory panel meeting
giovedì 30 luglio 2026·biopharmadive.com
Replimune melanoma drug wins support of FDA panel
The positive vote came despite persistent concerns from FDA scientists and positions the company to bounce back from two earlier rejections.

4 g fa

Replimune melanoma drug wins support of FDA panel

The positive vote came despite persistent concerns from FDA scientists and positions the company to bounce back from two earlier rejections.

Leggi questa versione → originale

benzinga.com2 g fa

Replimune Skin Cancer Therapy Hopes Revive After Positive FDA Panel Vote - Replimune Group (NASDAQ:REPL)

FDA advisory panel backed Replimune's RP1 melanoma data ahead of the agency's August 2 decision despite earlier staff criticism.

Leggi questa versione → originale

endpoints.news3 g fa

Replimune defends melanoma drug decisions to adcomm, parrying FDA skepticism

Replimune defends its single-arm RP1 melanoma trial data as an FDA advisory panel prepares to vote on whether results are interpretable and RP1 works.

Leggi questa versione → originale

statnews.com3 g fa

FDA expert committee votes in favor of Replimune’s melanoma treatment

STAT is live-blogging a meeting of FDA experts to review Replimune’s experimental melanoma drug, RP1.

Leggi questa versione → originale

giovedì 30 luglio 2026·

statnews.com

FDA expert committee votes in favor of Replimune’s melanoma treatment

STAT is live-blogging a meeting of FDA experts to review Replimune’s experimental melanoma drug, RP1.

giovedì 30 luglio 2026·

medpagetoday.com

Twice-Rejected Melanoma Drug Gets Surprise Love From FDA Panel

Vote at odds with FDA reviewers

giovedì 30 luglio 2026·

endpoints.news

Replimune defends melanoma drug decisions to adcomm, parrying FDA skepticism

Replimune defends its single-arm RP1 melanoma trial data as an FDA advisory panel prepares to vote on whether results are interpretable and RP1 works.

venerdì 31 luglio 2026·

benzinga.com

Replimune Skin Cancer Therapy Hopes Revive After Positive FDA Panel Vote - Replimune Group (NASDAQ:REPL)

FDA advisory panel backed Replimune's RP1 melanoma data ahead of the agency's August 2 decision despite earlier staff criticism.

Twice-Rejected Melanoma Drug Gets Surprise Love From FDA Panel

Timeline cronologica

FDA Staff Unconvinced Drug for Melanoma Shows Benefit

Replimune melanoma drug wins support of FDA panel

Replimune melanoma drug wins support of FDA panel

Replimune Skin Cancer Therapy Hopes Revive After Positive FDA Panel Vote - Replimune Group (NASDAQ:REPL)

Replimune defends melanoma drug decisions to adcomm, parrying FDA skepticism

FDA expert committee votes in favor of Replimune’s melanoma treatment

FDA expert committee votes in favor of Replimune’s melanoma treatment

Twice-Rejected Melanoma Drug Gets Surprise Love From FDA Panel

Replimune defends melanoma drug decisions to adcomm, parrying FDA skepticism

Replimune Skin Cancer Therapy Hopes Revive After Positive FDA Panel Vote - Replimune Group (NASDAQ:REPL)